Ilan Blatt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ilan Blatt has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Dana Ekstein
Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
3 shared publications Miri Neufeld
2 shared publications- Sara Eyal
The Hebrew University of Jerusalem
2 shared publications - Amelia Ruffatti
Rheumatology Unit, Department of Medicine, University Hospital of Padua, Padua, Italy
1 shared publication - Andreas Jönsen
Department of Clinical Sciences Lund, Rheumatology, Lund University, SE-222 42 Lund, Sweden
1 shared publication - Angela Tincani
Spedali Civili and University of Brescia
1 shared publication
Latest Publications
- 1 August 2016
- Published by Elsevier in Epilepsy & Behavior
- Vol. 61, 82-85
Utilization of antiepileptic drugs in Israel
- 1 August 2016
- Published by Elsevier in Epilepsy & Behavior
- Vol. 61, 82-85
Utilization of antiepileptic drugs in Israel
- 1 April 2016
- Published by Elsevier in Reproductive Toxicology
- Vol. 60, 176
The necessity of therapeutic levetiracetam (Keppra®) monitoring during pregnancy: A prospective study
- 1 April 2016
- Published by Elsevier in Reproductive Toxicology
- Vol. 60, 176
The necessity of therapeutic levetiracetam (Keppra®) monitoring during pregnancy: A prospective study
- 1 January 2016
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 34, 60-65
An evaluation of pharmacist knowledge on treatment with antiepileptic drugs
- 1 January 2016
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 34, 60-65
An evaluation of pharmacist knowledge on treatment with antiepileptic drugs
- Open Access
- 14 May 2015
- Published by Springer Nature in BMC Neurology
- Vol. 15 (1) , 1-7
Asystole in the epilepsy unit
Early identification of cardiac asystole as a reason for syncope is of uttermost significance, as insertion of a cardiac pacemaker can save the patient’s life and prevent severe injury. The aim of this work was to emphasize the subtle and unusual presentations of asystole in patients evaluated in epilepsy units. We reviewed the clinical presentation, ECG and EEG data of a series of seven patients who were evaluated in four epilepsy units and were diagnosed with asystole. Three patients had unusual clinical manifestations of cardiac asystole, resembling epileptic seizures. Three patients had asystole induced by epileptic seizures and in one patient the diagnosis was not clear. All patients except one were implanted with a pacemaker and improved clinically. Seizure-induced asystole is a rare complication of epilepsy and asystole may clinically mimic epileptic seizures. A high level of suspicion and thorough prolonged cardiac and EEG monitoring are mandatory for reaching the right diagnosis. As the diagnosis is rare and difficult to reach, a flow chart to assist diagnosis is suggested.
- 14 May 2015
- Published by Springer Nature in BMC Neurology
- Vol. 15 (1) , 1-7
Open AccessAsystole in the epilepsy unit
Early identification of cardiac asystole as a reason for syncope is of uttermost significance, as insertion of a cardiac pacemaker can save the patient’s life and prevent severe injury. The aim of this work was to emphasize the subtle and unusual presentations of asystole in patients evaluated in epilepsy units. We reviewed the clinical presentation, ECG and EEG data of a series of seven patients who were evaluated in four epilepsy units and were diagnosed with asystole. Three patients had unusual clinical manifestations of cardiac asystole, resembling epileptic seizures. Three patients had asystole induced by epileptic seizures and in one patient the diagnosis was not clear. All patients except one were implanted with a pacemaker and improved clinically. Seizure-induced asystole is a rare complication of epilepsy and asystole may clinically mimic epileptic seizures. A high level of suspicion and thorough prolonged cardiac and EEG monitoring are mandatory for reaching the right diagnosis. As the diagnosis is rare and difficult to reach, a flow chart to assist diagnosis is suggested.
- 1 April 2007
- Vol. 146 (4) , 269-71, 318
[Efficacy and safety of levetiracetam (keppra) add-on treatment in adult patients with refractory epilepsy in two tertiary centers].
Levetiracetam (LEV) is a new generation anti-epileptic drug, which has been approved as add-on therapy for partial epilepsy. The mechanism of LEV is not yet completely understood. To evaluate the efficacy and tolerability of LEV in adult patients with refractory epilepsy. We report the results of 49 patients with refractory epilepsy, with partial and generalized seizures, who received LEV as an add-on treatment, in two tertiary medical centers. There were 27 males, mean age 35.4+13 years. The average duration of epilepsy was 21 + 11 years, the average seizure rate was 31 + 30 per month. The patients were treated with a mean of 2.6 AED when LEV was introduced. The patients were treated for 12.6 + 9.7 months with an average dose of 1964 + 743.7 mg LEV per day. Five (10%) patients became seizure free, 12 (25%) responded with seizure reduction of more than 50% following the introduction of LEV, 8 (16%) responded with seizure reduction of less than 50%, no response to LEV was reported in 20 (41%) and seizure aggravation occurred in 4 (8%). No serious persistent adverse events were reported. The main side effect was drowsiness in 10% of patients. The results of this study, as well as previous studies, suggest that LEV is a well-tolerated new antiepileptic drug, and as an add-on therapy it may effectively improve seizure control in patients with intractable epilepsy.
- 1 April 2007
- Vol. 146 (4) , 269-71, 318
[Efficacy and safety of levetiracetam (keppra) add-on treatment in adult patients with refractory epilepsy in two tertiary centers].
Levetiracetam (LEV) is a new generation anti-epileptic drug, which has been approved as add-on therapy for partial epilepsy. The mechanism of LEV is not yet completely understood. To evaluate the efficacy and tolerability of LEV in adult patients with refractory epilepsy. We report the results of 49 patients with refractory epilepsy, with partial and generalized seizures, who received LEV as an add-on treatment, in two tertiary medical centers. There were 27 males, mean age 35.4+13 years. The average duration of epilepsy was 21 + 11 years, the average seizure rate was 31 + 30 per month. The patients were treated with a mean of 2.6 AED when LEV was introduced. The patients were treated for 12.6 + 9.7 months with an average dose of 1964 + 743.7 mg LEV per day. Five (10%) patients became seizure free, 12 (25%) responded with seizure reduction of more than 50% following the introduction of LEV, 8 (16%) responded with seizure reduction of less than 50%, no response to LEV was reported in 20 (41%) and seizure aggravation occurred in 4 (8%). No serious persistent adverse events were reported. The main side effect was drowsiness in 10% of patients. The results of this study, as well as previous studies, suggest that LEV is a well-tolerated new antiepileptic drug, and as an add-on therapy it may effectively improve seizure control in patients with intractable epilepsy.
- 1 July 2004
- Vol. 31 (7) , 1344-8
Features associated with epilepsy in the antiphospholipid syndrome.
To assess the frequency of epilepsy in primary and secondary antiphospholipid syndrome (APS); to analyze the clinical and laboratory features characterizing those with epilepsy in a cohort of 538 patients with APS; and to find associated features that would suggest risk factors for epilepsy in APS. We analyzed the clinical features of patients with APS who had epilepsy and compared them to the clinical features of non-epileptic APS patients. Of 538 APS patients, 46 (8.6%) had epilepsy. Epilepsy was more prevalent among APS secondary to systemic lupus erythematosus (SLE) compared to primary APS (13.7% vs 6%; p < 0.05). The patients with epilepsy had a higher prevalence of central nervous system (CNS) manifestations including focal ischemic events (strokes or transient ischemic events, 54.3% vs 24.6%; p < 0.0001) and amaurosis fugax (15.2% vs 4.9%; p < 0.05). APS patients with epilepsy had a higher frequency of valvular pathology (30.4% vs 14.6%; p < 0.01), thrombocytopenia (43.5% vs 25%; p < 0.05), and livedo reticularis (26.1% vs 11.5%; p < 0.01). The multivariate logistic regression analysis found CNS thromboembolic events as the most significant factor associated with epilepsy, with an odds ratio (OR) of 4.05 (95% confidence interval, CI: 2.05-8), followed by SLE (OR 1.4, 95% CI 1.2-4.7), and valvular vegetations (OR 2.87, 95% CI 1-8.27). Epilepsy is common in APS and most of the risk seems to be linked to vascular disease as manifested by extensive CNS involvement, valvulopathy, and livedo reticularis and to the presence of SLE. These factors, however, explain only part of the increased occurrence of epilepsy in APS and other causes such as direct immune interaction in the brain should be investigated.
- 1 July 2004
- Vol. 31 (7) , 1344-8
Features associated with epilepsy in the antiphospholipid syndrome.
To assess the frequency of epilepsy in primary and secondary antiphospholipid syndrome (APS); to analyze the clinical and laboratory features characterizing those with epilepsy in a cohort of 538 patients with APS; and to find associated features that would suggest risk factors for epilepsy in APS. We analyzed the clinical features of patients with APS who had epilepsy and compared them to the clinical features of non-epileptic APS patients. Of 538 APS patients, 46 (8.6%) had epilepsy. Epilepsy was more prevalent among APS secondary to systemic lupus erythematosus (SLE) compared to primary APS (13.7% vs 6%; p < 0.05). The patients with epilepsy had a higher prevalence of central nervous system (CNS) manifestations including focal ischemic events (strokes or transient ischemic events, 54.3% vs 24.6%; p < 0.0001) and amaurosis fugax (15.2% vs 4.9%; p < 0.05). APS patients with epilepsy had a higher frequency of valvular pathology (30.4% vs 14.6%; p < 0.01), thrombocytopenia (43.5% vs 25%; p < 0.05), and livedo reticularis (26.1% vs 11.5%; p < 0.01). The multivariate logistic regression analysis found CNS thromboembolic events as the most significant factor associated with epilepsy, with an odds ratio (OR) of 4.05 (95% confidence interval, CI: 2.05-8), followed by SLE (OR 1.4, 95% CI 1.2-4.7), and valvular vegetations (OR 2.87, 95% CI 1-8.27). Epilepsy is common in APS and most of the risk seems to be linked to vascular disease as manifested by extensive CNS involvement, valvulopathy, and livedo reticularis and to the presence of SLE. These factors, however, explain only part of the increased occurrence of epilepsy in APS and other causes such as direct immune interaction in the brain should be investigated.
- 1 September 2003
- Vol. 5 (9) , 677-8
Decompressive hemicraniectomy as a lifesaving procedure in severe acute ischemic stroke.
- 1 September 2003
- Vol. 5 (9) , 677-8
Decompressive hemicraniectomy as a lifesaving procedure in severe acute ischemic stroke.